A Look at Future Advancements in Medical Operations Print E-mail
By BioMedReports.Com   
Friday, 15 March 2019 03:43
icon_newsnotesPredictions have been made by an independent Commission on the Future of Surgery which was set up by the UK’s Royal College of Surgeons that a raft of state-of-the-art technology is going to transform the way medical surgery is carried out.
Read more...
 
Numerous Upcoming Catalysts Should Drive Demand for Q BioMed’s Low-Float Shares Print E-mail
By M.E.Garza   
Thursday, 07 March 2019 03:20
icon_MarketCatalyst Q BioMed (OTCQB:QBIO), has been getting attention from biotech investors and pharma industry publications for its “upside down” biotech business model. The company expects to continue making strides in developing their product offerings and appears well positioned to generate revenue in 2019 and beyond.
Read more...
 
Big Healthcare Market Movers Print E-mail
By BioMedReports.Com   
Wednesday, 06 March 2019 00:52
icon_MarketReportUPOver the years, Investors have seen biotech companies as risky yet very profitable ventures. Mostly, this is due to the cutthroat competition where these companies have to come up with the best innovations in the healthcare department.
Read more...
 
Demand for New Glaucoma Therapies Has Greatest Potential to Drive Value for Q BioMed’s Shareholders Print E-mail
By Staff and Wire Reports   
Friday, 08 February 2019 02:51
icon_pipelineprogressQ BioMed (OTCMKTS: QBIO) has announced that it is bringing innovation to the treatment of Glaucoma- the the leading cause of irreversible blindness globally.
Read more...
 
Breast Cancer Clinical Trial Results Send Shares Soaring Print E-mail
By Staff and Wire Reports   
Wednesday, 06 February 2019 00:00
icon_marketmoverShares of MacroGenics, Inc. (NASDAQ: MGNX) soared after the company announced positive results from SOPHIA, the Company’s Phase 3 clinical study of margetuximab in HER2-positive metastatic breast cancer patients.
Read more...
 
Imminent FDA Decision Prompts the Ignition of Q BioMed's Shares Print E-mail
By M.E.Garza   
Thursday, 17 January 2019 13:15
icon_alert_keyAn anticipated key FDA decision is set to transform Q BioMed (OTCMKTS: QBIO) from a biotech developer to a revenue generating manufacturer in what may be record time. That imminent event is already attracting interest from traders and investors, but a game changing plan revealed by the CEO may be an even stronger reason to focus on this emerging biotechnology accelerator.
Read more...
 
Three Biotech Stocks Moving Markets in Early 2019 Trading Print E-mail
By M.E.Garza   
Tuesday, 08 January 2019 02:47
icon_marketmoverThese three biotechs have kicked off the new year in a very bullish way, but where do things go from here for Novavax, Q Biomed and Axsome Therapeutics?
Read more...
 
Why investors are accumulating shares of Sophiris Bio (SPHS) and Transenterix Inc. (TRXC) Print E-mail
By M.E.Garza   
Friday, 29 June 2018 00:04
Icon_alert_keyShares of Transenterix Inc (NYSE: TRXC) and Sophiris Bio (NASDAQ:SPHS) have seen record numbers in trading volume this week, yet despite solid footing, both firms have seen their share prices rocked by unexpected news.
Read more...
 
New Class of Medicinals based on Cannabinoid Molecules, Spurs NEMUS Bioscience Inc. into Action Print E-mail
By Staff and Wire Reports   
Wednesday, 21 September 2016 11:38
Q&A with Brian Murphy MD, CEO/CMO, NEMUS Bioscience Humans produce a range of chemical compounds called cannabinoids that keep the human body stable by binding to receptors on cell membranes and controlling the release of chemical messengers that regulate everything from how humans experience pain to our moods. While most people's endocannabinoid systems naturally help maintain a state of homeostasis, or stability, conditions such as multiple sclerosis or treatments for diseases like cancer can throw off that balance. Introducing cannabinoids made outside the body might help. Marijuana also contains cannabinoids – at least 66 of them.
Read more...
 
CEO of emerging NanoAntibiotics Says Firm is Poised for Growth in Biotech’s Potent Liver Disease Space Print E-mail
By M.E.Garza   
Thursday, 07 July 2016 07:10
Jonathan Adams is CEO of NanoAntibiotics, Inc. (OTCQB:NNAB) [nanoantibiotics.com], which will soon change its name to BioVie.
Read more...
 
<< Start < Prev 1 2 3 4 5 6 7 8 9 10 Next > End >>

Page 1 of 56

Newsletter